Citadel Advisors LLC raised its holdings in Audentes Therapeutics Inc (NASDAQ:BOLD) by 981.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 110,921 shares of the biotechnology company’s stock after acquiring an additional 100,663 shares during the quarter. Citadel Advisors LLC owned 0.40% of Audentes Therapeutics worth $3,107,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Audentes Therapeutics in the third quarter valued at $143,000. Nationwide Fund Advisors lifted its holdings in Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 6,384 shares during the period. Trexquant Investment LP acquired a new position in shares of Audentes Therapeutics during the 3rd quarter worth $295,000. State of Wisconsin Investment Board acquired a new position in shares of Audentes Therapeutics during the 2nd quarter worth $210,000. Finally, Rhumbline Advisers acquired a new position in shares of Audentes Therapeutics during the 2nd quarter worth $252,000. 78.99% of the stock is owned by institutional investors.
Several research analysts have recently issued reports on the company. Bank of America reaffirmed a “buy” rating and set a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Evercore ISI assumed coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $23.00 price target for the company. Zacks Investment Research downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Raymond James Financial assumed coverage on Audentes Therapeutics in a research note on Thursday, October 12th. They set a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $27.17.
Audentes Therapeutics Inc (NASDAQ BOLD) opened at $28.38 on Friday. Audentes Therapeutics Inc has a one year low of $13.90 and a one year high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.88). equities analysts predict that Audentes Therapeutics Inc will post -3.52 EPS for the current year.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
What are top analysts saying about Audentes Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics Inc and related companies.